Clinical Trials
14 trialsNCT01343173 2026-05-19
STIM 2
University Hospital, Bordeaux
Phase NA Completed
NCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed
NCT04795427 2025-04-18
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Phase 2 Completed
NCT02743351 2023-02-08
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
Phase 1/2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT02085798 2020-01-27
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Celgene
Completed
NCT02164071 2019-11-18
GAH
Celgene
Completed
NCT02891551 2019-07-24
OCEAN
Celgene
Completed
NCT00038597 2018-10-30
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT01819389 2014-01-07
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Hospital Universitario Dr. Jose E. Gonzalez
Phase 3 Completed
NCT00478985 2013-07-02
STIM
University Hospital, Bordeaux
Phase NA Completed
NCT00103701 2011-04-14
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 1 Completed